Wystepowanie Staphylococcus aureus o obnizonej wrazliwosci na antybiotyki glikopeptydowe wsrod szczepow izolowanych z klinicznego materialu w 2002 roku

• Autorzy: Mlynarczyk A. , Mlynarczyk G. , Luczak M.
• Języki publikacji: PL

Abstrakty

PL

Badano występowanie GISA i h-GVISA wśród MRSA izolowanych w naszym laboratorium. W materiale badanym stwierdzono 5 szczepów, które można bylo zaliczyć do h-GISA oraz nie stwierdzono szczepu GISA. Nie stwierdzono wzrostu częstości występowania szczepów h-GISA w stosunku do lat ubiegłych. Zaobserwowano znaczny wpływ wyjściowego inokulum bakteryjnego na kształt krzywej w analizie populacyjnej badanych oraz wzorcowych szczepów S. aureus wrażliwych, GISA i h-GISA.

EN

The methicillin-resistant strains of S. aureus (MRSA) isolated in our laboratory were searched for strains with decreased susceptibility to glycopeptides, GISA (glycopeptide intermediate Staphylococcus aureus) and hetero-GISA strains. 103 strains isolated in 2002 were investigated. Five h-VISA and none VISA strain were found. There was not observed any increase in the frequency of VISA and h-VISA comparing to the former years. In the case of some clinical as well as standard strains (susceptible, GISA and especially h-GISA) the start inoculum significantly influenced a shape of the growth curve obtained as a result of the population analysis.

Słowa kluczowe

PL

analiza populacyjna; szczepy bakteryjne; opornosc na antybiotyki; wankomycyna; antybiotyki glikopeptydowe; Staphylococcus aureus

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2003
• Tom: 55
• Numer: 3
• Opis fizyczny: s.209-217,wykr.,bibliogr.

Twórcy

autor

Mlynarczyk A.

• Akademia Medyczna, Warszawa

autor

Mlynarczyk G.

autor

Luczak M.

Bibliografia

• 1. Chang S, Sievert DM, Hageman JC i inni. Vancomycin-resistant Staphylococcus aureus investigative team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
• 2. Cui L, Ma X, Sato K i inni. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41: 5-14.
• 3. Hanaki H, Labischinski H, Inaba Y i inni. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 1998; 42: 315-20.
• 4. Hiramatsu K, Aritaka N, Hanaki H i inni. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
• 5. Howe RA, Wootton M, Walsh TR i inni. Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus. J Antimicrob Chemother 1999; 44: 675-8.
• 6. Hubert SK, Mohammed JM, Fridkin SK i inni. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 1999; 37: 3590-3.
• 7. Jeljaszewicz J, Młynarczyk G, Młynarczyk A. Antibiotic resistance in Gram-positive cocci. Int J Antimicrob Agents 2000; 16: 473-78.
• 8. Kim MN, Hwang SH, Pyo YJ, Mun HM, Pai CH. Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J Clin Microbiol 2002; 40: 1376-80.
• 9. Krzyszton-Russjan J, Gniadkowski M, Polowniak-Pracka H i inni. The first Staphyloaureus isolates with reduced susceptibility to vancomycin in Poland. J Antimicrob Chemother 2002; 50: 1065-9.
• 10. Kuroda M, Ohta T, Uchiyama I i inni. Whole genome sequencing of methicillin-resistant Staphylococcus aureus, the major hospital pathogen. Lancet 2001; 357: 1225-40.
• 11. Marchese A, Balistreri G, Tonoli E i inni. Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38: 866-9.
• 12. Marlowe EM, Cohen MD, Hindler JF i inni. Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience. J Clin Microbiol 2001; 39: 2637-9.
• 13. Młynarczyk G, Młynarczyk A, Łuczak M. VISA i hetero-VISA wśród szczepów Staphylococcus aureus izolowanych z przypadków klinicznych. Med Dośw Mikrobiol 2002; 54: 9-20.
• 14. Peschel A, Vuong C, Otto M, Gotz F. The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother 2000; 44: 2845-7.
• 15. Sakoulas G, Eliopoulos GM, Moellering RC Jr i inni. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46: 1492-502.
• 16. Sieradzki K, Leski T, Dick J i inni. Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J Clin Microbiol 2003; 41: 1687-93.
• 17. Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181: 7566-70.
• 18. Singh VK, Schmidt JL, Jayaswal RK, Wilkinson BJ. Impact of sigB mutation on Staphylococcus aureus oxacillin and vancomycin resistance varies with parental background and method of assessment. Int J Antimicrob Agents 200; 21: 256-61.